While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.
Compare HGEN Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Humanigen Inc
One is growing revenue. And the other may soon launch its first product.
Detailed results from a late-stage study of the company's lead candidate were published online.
They're both innovating in attractive areas where there's no competition on the radar.
New coronavirus projects make them easy to hype, but they could face strong headwinds soon.
They're approaching the treatment-race finish line.
It's a definite maybe.
The company announced the pricing of a secondary stock offering.
The company's investigational coronavirus treatment could hit the market soon.
The company announced an important change to one of its ongoing clinical trials.